CO- AND TER-POLYMERS OF ALKYL- AND CHLOROALKYL VINYL ETHERS, MALEIC ANHYDRIDE AND MALEIMIDE HAVING ANTITUMOR ACTIVITY

Abstract: Low molecular weight co- and ter-polymers of lower alkyl- and chloroalkyl-substituted vinyl ethers and maleic anhydride in which from 0 mol percent to about 50 mol percent of the maleic anhydride is replaced with maleimide, said co- and ter-polymers having average molecular weights less than about 5000 and derivatized to contain half-amide, half-carboxyl acid groups in which from 0 weight percent to about 25 weight percent of the half-amide, half-carboxyl acid groups are converted to imide groups, and the pharmaceu­ tically acceptable cationic salt derivatives of said derivatized co- and ter-polymers, have antitumor activity.

Description: Co- AND TER-POLYMERS OF ALKYL- AND CHLOROALKYL VINYL ETHERS, MALEIC ANHYDRIDE AND MALEIMIDE HAVING ANTITUMOR ACTIVITY This invention relates to pharmaceutically acceptable amide and imide derivatives of low molecular weight co- and ter-polymers of lower alkyland chloroalkyl-substituted vinyl ethers, maleic anhydride and maleimide having antitumor activity. Copolymers of alkyl vinyl ethers and maleic anhydr ide are known in the art as are the amide and imide derivatives thereof. These are generally high molecular weight resins useful in non-pharmaceutical applications such as binders, coatings, elastomers, paper, textiles and the like products. For example, U.S. Patent 2,313,565 describes the preparation of such resins by the catalyzed polymerization of ethyl vinyl ether and maleic anhydride from which the amide and imide derivatives are then made by further reaction with ammonia or with aliphatic and aromatic amines. U.S. Patent 2,944,033 describes similar such production of am ides and imides by ammoniation of copolymers of methyl vinyl ether and maleic anhydride. Butyl vinyl ethers and maleic anhydride are included in extensive lists of various monomeric components of polymeric materials which can be ammoniated to am ides and imides in U.S. Patents 3,157,595 and 3,998,907. The disclosed use of these derivatized copolymers is for clarification of water and for preparation of elastomeric products, respectively. Use of maleimide-containing monomeric substances as dibasic acid components for reaction with olefins, or as a third component to replace part of the anhydride component in the copolymerization of olefjns and polycarboxylic anhydrides, is described in Canadian Patent 664,326 and U.S. Patent 3,157,595, respectively. Pharmaceutically active copolymers of divinyl ether and maleic anhydride are known such as those described in U.S. Patents 3,224,943 and 3,794,612 and by Breslow in Pure & Appl. Chem. 46, 103-113 (1976). However, these polymeric materials are relatively high molecular weight substances of 5000 and greater molecular weight. Low molecular weight. polymeric materials with both amide and imide functionality and having antitumor properties are described in U.S. Patent 4,255,537. The base copolymer is prepared by copolymerization of maleic anhydride and other polycarboxylic anhydrides with alkenes, such as ethylene and propylene as distinguished from alkenyl oxides such as vinyl ethers. The base copolymer molecular weight ranges from about 300 to about 1500 and the imide comprises about 5 wt. % to about 40 wt. X of the derivatized groups. Hodnett et 1., J. Ned Chem. 21 (7), 652-657 (1978), describe the antitumor activity of copolymers of isobutyl vinyl ethers and acrylic acid against Sarcoma 180. The disclosed molecular weights from viscosity measurements range from 49,000 to 250,000 (Table II). Description of the Invention It has now been found that certain amide and imide derivatives of low molecular weight co- and terpolymers of lower alkyl and chloroalkyl-substituted vinyl ethers, maleic anhydride and maleimide exhibit considerable antitumor activity. These are polymeric materials having average molecular weights less than about 5000 and in which the derivatized groups comprise amide and from 0 wt. % to about 25 wt. X imide. The underivatized copolymers are prepared from loweralkyl- and chloroalkyl-substi tuted vinyl ether and maleic anhydride whereas in the case of the terpolymers a portion of the maleic anhydride is reolaced with maleimide in the copolymerization. The alkyl groups preferably have from about 2 to about 4 carbon atoms. The base co- and ter-polymers can be prepared by catalyzed polymerization methods well known in the art. Typically, the lower alkyl- and chloroalkylsubstituted vinyl ethers are reacted with maleic anhydride in the presence of a free-radical promoting catalyst initiator and a liquid solvent that is a solvent for the reactants and a nonsolv ent for the polymeric product. Conventional peroxide type and azo type free-radical promoting polymerization catalysts are suitable for this purpose such as, for example, benzoyl peroxide, t-butyl peroxypivalate, t-butyl peroctoate and azobisisobutyronitrile. A particularly useful catalyst system for the polymerization is the combination of organoboron compounds and organic peroxygen compounds as describ d in U.S. Patent 3,275,611. Use of a lower trialkylboron such as triethylboron and aliphatic or aryl hydroperoxide such as t-butylhydroperoxide or cumene hydroperoxide respectively, are especially preferred. The polymerization reaction can take place in conventional polar or nonpolar solvent media, for example, alkylated aromatic hydrocarbons such as ethyl benzene and ketones such as acetone and methyl ethyl ketone. Tetrahydrofuran (THF) is a particularly suitable choice for the solvent medium. Solution polymerization of monomers in THF at about 300 C using a triethylboron and t-butyl hydroperoxide initiating system is especially useful and enables the preparation of polymers with non-aromatic end groups. It will be appreciated that certain aromatic free-radical initiators, both through initiation of the polymerization reaction and subsequent termination or telomerization with certain aromatic solvent media, can cause the introduction of various aromatic moieties into the polymeric structure. For example, use of benzoyl peroxide as the free-radical initiator and ethyl benzene as the liquid reaction medium can cause introduction of their respective aromatic moieties into the polymeric structure. The copolymer preferably contains substantially equimolar quantities of the alkyl- or chloroalkylsubstituted vinyl ether and maleic anhydride residues as will be obtained by use of about equimolar quantities of the reactant monomers. A portion of the maleic anhydride can be replaced with maleimide in the polymerization reaction to produce a ter-polymer. Introduction of maleimide during the polymerization is a convenient means of introducing a known amount of imide into the polymer. Generally from 0 mol % to about 50 mol X but preferably from about 5 mol % to about 20 mol % of the maleic anhydride can thus be replaced by maleimide to produce the terpolymer. Following preparation of the base co- and terpolymer, derivatization to the antitumor active amide and imide products is carried out by appropriate ammoniation to form amide and imide derivatives such that from about 0% to about 25% by weight of the derivatized groups are imide groups. Ammoniation can be carried out by reaction with ammonia gas or aqueous ammonium hydroxide or by reaction with ammonia in organic solvent media. Ammoniatdon will generally result in formation of amide as well as ammonium salt groups. Heating at elevated temperature for an extended period of time to drive off water from the molecule will result in formation of imide groups. When maleimide is used in the initial polymerization step as a partial substitute for maleic anhydride, the foregoing imidation step may not be required unless a higher percent age of imide than initially prepared is desired in the final product. For example, if about 20X imide is de sired in the final product and 15Z imide is provided by use of maleimide in the initial polymerization reaction, an additional 5% imide can be prodded by the forms going imidation reaction. The ammoniation can be conveniently carried out by reaction of anhydrous ammonia with the co- and terpolymers in organic solvent media such as, for example, tuluene and THF, at temperature of from about 20 C to about 50 C for about 0.5 to about 2 hours and preferably from about 25 0C to about 35 0C for about 0.5 to about one hour. The reaction, which can be initiated at ambient temperature, is exothermic and will cause the temperature to rise. Continued ammoniation will then cause the reaction temperature to return to room temperature after the initial exothermic reaction. The ammonium salt group which exists in the amide and imide derivatives of the co- and ter-polymer can be converted to any other pharmaceutically acceptable cat ironic salt form such as, for example, sodium and potassium. Thus, conversion to illustrative sodium and potassium salt forms can be readily carried out by ion exchange of the ammonium salt with well known Rohm and Haas IRC-120 resin and similar such conventional ion-exchange resins in the sodium and potassium ion forms, respectively. The molecular weight of the amine and imide derivatized co- and ter-polymers of the present invention can be estimated in terms of the number average molecular weight or in terms of intrinsic viscosity. The number average molecular weight (Mn) of these polymeric materials as determined by Vapor Pressure Osmometry in dimethylformamide (DMF) at 900C generally lies between about 400 and about 5000 and preferably ranges from about 800 to about 3000. Specific viscosity of a 0.5 solution in THF at 250C generally lies between about 0.01 and about 0.08 dl/g and preferably ranges from about 0.01 to about 0.03 dl/g. The derivatized co- and ter-polymer products as prepared above can be placed into any suitable dosage form for the desired end use and administered to a warm-blooded animal by a variety of parenteral routes, especially intravenously and intraperitoneally. Such administration preferably is in aqueous solution such as in sterile water, physiologically normal saline (0.9X NaCl) and the like sterile injectable forms and can be carried out by suitable reconstitution of solid product. The derivatized copolymer pro ducts also can be administered orally in the form of tablets, powders, capsules, eel fixers and the like dosage forms. The active products can be used in admixture with common solid and liquid fillers, dilu ents, carriers, suspending agents and adjuvants such as, for example, cornstarch, lactose, talc, stearic acid, magnesium stearate, carboxymethyl cellulose, gelatin, acacia and locust bean gums, alcohol, water, dimethylsulfoxide, vegetable oils and the like pharma ceutically acceptable materials. The liquid oral dosage form also preferably is solid reconstituted in liquid mixture at the time of administration in order to maintain stability of the dual groupings of amide and imide. Dosages can vary widely as will be apparent from the more detailed illustrative examples set forth hereinbelow. Thus, in tests for activity against Lewis lung carcinoma implanted subcutaneously in B6D2F1 mice, substantial inhibition of primary tumor growth was observed in animals treated with the co- and ter-polymers made in accordance with this invention when administered over a wide range of dosage. The Lewis lung carcinoma is generally recognized as a severely intractable tumor condition against which most antitumor compounds are ineffective. The following detailed examples will further illustrate the invention although it will be appreciated that the invention is not limited to these specific examples. EXAMPLE 1 Butyl vinyl ether/?Ialeic anhydride Copolymer Derivative Polymer Preparation A 500 ml jacketed resin pot fitted with a mechanical stirrer, N2 inlet and condenser, a rubber septum for addition of the monomer, and a glass stopper was used as the reaction vessel. The resin pot was charged with the following monomer solution: 24.5 g maleic anhydride in 150 ml of ethylbenzene. Water was pumped through the jacket at 30 C. A second monomer solution consisting of 32 ml (25 9) of butyl vinyl ether, 68 ml ethylbenzene, and 2 ml of cumene hydroperoxide was mixed with N2 in a 100 ml graduated cylinder. This solution was transferred to a 100 cc syringe attached to a syringe pump and added to the resin pot at about 0.28 ml/min. Addition was completed in 6 hours. Also, 2 ml of triethylborane (1M in THF) was added every hour, during the adding'on of the butyl vinyl ether, for a total of 12 ml. At the end of addition, the polymer was collected on a coarse fritted glass funnel, washed with hexane, re-filtered and dried in a vacuum oven at 90 0C overnight.. Yield = 33.2 g; sp. visc. (0.5% in THF at 25 C)= 0.032. Amidation 25. g of the above-prepared polymer was dissolved in 200 ml of THF and transferred to a 100 cc syringe attached to a syringe pump. This solution was added at 10 ml/min to a 500 ml, 4-neck flask. The flask was fitted with a mechanical stirrer, gas dispersion tube, thermowell, and a condenser through which the polymer solution was injected via a small tube into 200 ml of THF in the flask. Anhydrous ammonia was bubbled in throughout the reaction period and produced a small exotherm from the addition of the polymer. ' After the react ion returned to room tempera ture (about 2 hours) , the amp dated polymer was collected on a coarse, tritted glass funnel and dried in a dessicator under vacuum overnight. Imidation All of the above amidated polymer was placed in a 500 ml, 4-neck flask containing 250 ml of toluene. The flask was fitted with a mechanical st,rrer, thermowell, gas dispersion tube, and a condenser with a water trap. The slurry was refluxed for 4 hours with anhydrous ammonia bubbling in at a slow rate and any water was captured in the trap. At the end of the imidation the mixture was cooled to room temperature and the polymer filtered onto the glass funnel, washed with hexane, filtered and dried in a dessicator under vacuum overnight. Imide = 16% The amide-imide polymer was then mixed in about 200 ml of de-ionized water and the pH adjusted to 9.5 with concentrated NH4OH. This resulted in a solution which was filtered through a 0.2 0.2,u filter and freeze dried prior to submission for pharmaceutical evaluation. Yield = 23.6 g EXAMPLE 2 Butyl vinyl ether/Maleic anhydride/ Maleimide Terpolymer Derivative Polymer Preparation A 300 ml , jacketed resin pot fitted with a mechanical stirrer, N2 inlet and condenser, a rubber septum for introduction of the monomer solution, and a glass stopper was used as the reaction vessel. The resin pot was charged with 8.5 g maleic anhydride, 3.7 g maleimide, and 75 ml THF. Triethylborane was added during the 6 hour reaction period at 1 ml/hr for a total of 6 ml. The jacket temperature was kept at 30 C. A second monomer solution consisting of 16 ml (12.5 g) butyl vinyl ether, 34 ml THF, and 0.5 ml t-butylhydroperoxide was added to the resin pot over the 6 hour reaction period at about 0.13 ml/min via a 100 cc syringe attached to a syringe pump. At the end of addition, the polymer was precipitated out into hexane and filtered onto a coarse, fritted glass funnel. It was then dried in a vacuum over at 90 0C overnight. Yield = 16.8 g; sp. visc. (0.5% in THF at 250 C) = 0.014. Ammonia t ion 14.6 g of the above-prepared polymer was dissolved in about 100 ml of THF and transferred to a 100 cc syringe on a syringe pump for addition at about 10 ml/min to a 500 ml, 4-neck flask. The flask was fitted with a mechanical stirrer, a thermowell, a condenser through which the polymer was introduced, and a gas dispersion tube. Anhydrous ammonia was bubbled into 200 ml of THF charged into the flask followed by addition of the polymer solution. Ammonia was introduced into the slurry throughout the reaction period. The addition produced an exotherm and after returning to room temperature (about 2 hrs.), the reaction was terminated. The amide-imide polymer was then filtered and dried in a dessicator under vacuum overnight. Imide = 20X 16.7 g of the amide-imide polymer was mixed in about 300 ml of de-ionized water and the pH adjusted to 9.5 with concentrated NH OH. This solution was filtered through a 0.2 filter and freeze dried prior to submission for pharmaceutical evaluation. Yield = 14.1 g. EXAMPLE 3 Butyl vinyl ether/Maleic anhydride/ Maleimide Terpolymer Derivative Polymer Preparation A 300 ml , jacketed resin pot was fitted with a stirrer, a N2 inlet and condenser, a rubber septum for introduction of the monomer solution, and a glass stopper. The resin pot was charged with 9.8 g maleic anhydride, 2.4 g maleimide, and 75 ml of ethylbenzene. Water was pumped through the jacket at 75 C. A second monomer solution consisting of 16.1 ml (12.5 g) of butyl vinyl ether, 1.0 g of 2,2'-Azobis [2methylpropionitrilei , and 34 ml of ethylbenzene was mixed with N2. This solution was transferred to a 100 cc syringe attached to a syringe pump for introduction to the pot at about 0.16 ml/min over 5 hrs. After addition was complete the mixture was cooled to room temperature and the polymer filtered out onto a coarse, fritted glass funnel, washed with hexane, re-filtered, and then dried in a vacuum oven at 90 C. overnight. Yield = 19.4 g; sp. visc. (0.5% in THF at 25 C)= 0.032 Ammoniation 18.1 g of the above-prepared polymer was dissolved in 150 ml of THF and transferred to a 100 c & syringe attached to a syringe pump for addition at about 10 ml/min to a 500 ml, 4-neck flask. The flask was fitted with a stirrer, thermowell, a condenser through which the polymer solution was added, and a gas dispersion tube. 200 ml of THF was added to the flask and anhydrous ammonia was bubbled in prior to addition of the polymer solu tt-on. The ammonia was introduced throughout the reaction period. The additior > -produced an exothermic reaction which returned to room temperature in about 2 hours. At this time the amide-imide polymer was filtered out and dried in a dessicator under vacuum overnight. Imide = 15% 25.5 g of the above amide-imide polymer was mixed in about 250 ml of de-ionized water and the pH was adjusted to 9.5 with concentrated NH40H. This solution was then filtered through a 0.2 filter and freeze dried prior to submission for pharmaceutical evaluation. Yield = 18.89. EXAMPLE 4 Samples of the final products prepared for pharmaceutical evaluation in accordance with Examples 1 to 3, above, were tested at various dosages for their antitumor activity against Lewis lung carcinoma. In this test, 106 Lewis lung cells were implanted sc in the right flank of B6D2F1 mice (10 per group). Male mice were used with product of Examples 1 and 3, while female mice were used with product of Example 2. The test products were dissolved in 0.9% NaCl solution and administered f.p. in a volume of 0.5 ml per mouse. Tumors were measured in perpendicular diameters on day 14 and tumor volume was calculated by the formula: length x width2 x 0.5. Mean and median tumor volumes were calculated for each treatment group (T) and were compared with untreated controls (C) to obtain a T/C ratio. Tables 1 to 3 set forth the results with product of Examples 1 to 3, respectively. TABLE 1 EMI15.1 <SEP> EVALUATION <SEP> OF <SEP> EXAPLE <SEP> 1 <SEP> PRODUCT <SEP> IN <SEP> sc <SEP> LEWIS <SEP> LUNG <SEP> CARCINOMA <tb> <SEP> Wt. <SEP> Change <SEP> (gm) <SEP> Tumour <SEP> Growth <SEP> Inhibition <SEP> (Day <SEP> 14) <tb> Dose <SEP> Median <tb> (mg/kg. <SEP> ip <SEP> Day <SEP> 7 <SEP> Day <SEP> 14 <SEP> N.P.a <SEP> Volume <SEP> T/Cb <SEP> Mean <SEP> Volume <SEP> T/Cb <tb> qD <SEP> 1-5) <SEP> (mm ) <SEP> (mm )# <SEP> S.D. <tb> 2000 <SEP> Toxic <SEP> - <SEP> 10/10 <SEP> dead <SEP> by <SEP> Day <SEP> 4 <tb> 800 <SEP> -2.8 <SEP> +1.9 <SEP> 1/4 <SEP> 160 <SEP> .11 <SEP> 144# <SEP> 127t <SEP> .10 <tb> 320 <SEP> -1.8 <SEP> +3.8 <SEP> 2/10 <SEP> 320 <SEP> .22 <SEP> 263# <SEP> 169t <SEP> .18 <tb> 128 <SEP> -0.6 <SEP> +3.2 <SEP> 0/10 <SEP> 700 <SEP> .49 <SEP> 810# <SEP> 592t <SEP> .56 <tb> 51.2 <SEP> +0.5 <SEP> +2.5 <SEP> 0/10 <SEP> 1131 <SEP> .79 <SEP> 1314# <SEP> 646 <SEP> .91 <tb> 20.5 <SEP> +0.7 <SEP> +2.6 <SEP> 0/10 <SEP> 1628 <SEP> 1.13 <SEP> 1769# <SEP> 778 <SEP> 1.23 <tb> 8.19 <SEP> +1.4 <SEP> +2.5 <SEP> 0/10 <SEP> 1186 <SEP> 1.31 <SEP> 1842# <SEP> 585 <SEP> 1.28 <tb> Untreated <tb> Controls <SEP> +2.0 <SEP> +1.7 <SEP> 0/10 <SEP> 1152# <SEP> 1194# <SEP> 516# <tb> <SEP> +2.1 <SEP> +2.9 <SEP> 0/8 <SEP> 1308#1437 <SEP> 1377# <SEP> 676#1444#600 <tb> <SEP> +2.0 <SEP> +2.0 <SEP> 0/10 <SEP> 1838# <SEP> 1959# <SEP> 681# <tb> <SEP> +2.3 <SEP> +3.0 <SEP> 0/7 <SEP> 1775# <SEP> 1699# <SEP> 582# <tb> a N.P. = mice without palpable tumors on day 14/total b T/C = ratio of tumor volume in treated group relative to untreated controls t = Significantly different from untreated control p < .01 by Student's qD = deily dosage, days 1 to 5 TABLE 2 EVALUATION OF EXAMPLE 2 PRODUCT IN sc LEWIS LUNG CARCINOMA EMI16.1 <SEP> Wt. <SEP> Change <SEP> (gm) <SEP> Tumour <SEP> Growth <SEP> Inhibition <SEP> (Day <SEP> 14) <tb> Dose <SEP> Median <tb> (mg/kg. <SEP> ip <SEP> Day <SEP> 7 <SEP> Day <SEP> 14 <SEP> N.P.a <SEP> Volume <SEP> T/Cb <SEP> Mean <SEP> Volume <SEP> T/Cb <tb> qD <SEP> 1-5) <SEP> (mm ) <SEP> (mm )# <SEP> S.D. <tb> 2000 <SEP> Toxic <SEP> 10/10 <SEP> dead <SEP> by <SEP> Day <SEP> 4 <tb> 800 <SEP> -2.9 <SEP> +2.5 <SEP> 3/6 <SEP> 63 <SEP> .04 <SEP> 103#143t <SEP> .06 <tb> 320 <SEP> +0.7 <SEP> +1.9 <SEP> 1/10 <SEP> 352 <SEP> .22 <SEP> 467#410t <SEP> .28 <tb> 128 <SEP> +2.4 <SEP> +0.8 <SEP> 0/10 <SEP> 458 <SEP> .29 <SEP> 857#856t <SEP> .51 <tb> 51.2 <SEP> +2.0 <SEP> +1.5 <SEP> 0/10 <SEP> 1085 <SEP> .68 <SEP> 1223#525 <SEP> .73 <tb> 20.5 <SEP> +1.1 <SEP> +1.6 <SEP> 0/9 <SEP> 1152 <SEP> .73 <SEP> 1132#560 <SEP> .68 <tb> 8.19 <SEP> +1.8 <SEP> +1.1 <SEP> 0/10 <SEP> 1204 <SEP> .76 <SEP> 1344#511 <SEP> .80 <tb> Untreated <tb> Controls <SEP> +1.6 <SEP> +1.5 <SEP> 0/10 <SEP> 1993# <SEP> 1960#498# <tb> <SEP> +1.5 <SEP> +0.9 <SEP> 0/10 <SEP> 1628#1587 <SEP> 1638#653#1676#608 <tb> <SEP> +1.6 <SEP> +1.1 <SEP> 0/10 <SEP> 1362# <SEP> 1555+821# <tb> <SEP> +3.1 <SEP> +0.7 <SEP> 0/10 <SEP> 1538# <SEP> 1551#357# <tb> a N.P. = mice without palpable tumors on day 14/total b T/C = ratio of tumor volume in treated group relative to untreated controls t = Significantly different from untreated control at 0 < 0.1 by Stundent's t test qD = deily dosage, days 1 to 5 TABLE 3 EVALUTATION OF EXAMPLE 3 PRODUCT IN sc LEWIS LUNG CARCINOMA EMI17.1 <SEP> Wt. <SEP> Change <SEP> (gm) <SEP> Tumour <SEP> Growth <SEP> Inhibition <SEP> (Day <SEP> 14) <tb> Dose <SEP> Median <tb> (mg/kg. <SEP> ip <SEP> Day <SEP> 7 <SEP> Day <SEP> 14 <SEP> N.P.a <SEP> Volume <SEP> T/Cb <SEP> Mean <SEP> Volume <SEP> T/Cb <tb> qD <SEP> 1-5) <SEP> (mm ) <SEP> (mm )# <SEP> S.D. <tb> 2000 <SEP> toxic <SEP> 10/10 <SEP> dead <SEP> by <SEP> Day <SEP> 4 <tb> 800 <SEP> toxic <SEP> 9/10 <SEP> dead <SEP> by <SEP> Day <SEP> 5 <tb> 320 <SEP> -2.5 <SEP> +2.0 <SEP> 3/8 <SEP> 59 <SEP> .04 <SEP> 89#101t <SEP> .06 <tb> 128 <SEP> -0.9 <SEP> +2.2 <SEP> 3/10 <SEP> 100 <SEP> .07 <SEP> 80#61t <SEP> .05 <tb> 51.2 <SEP> +0.8 <SEP> +0.8 <SEP> 1/10 <SEP> 294 <SEP> .20 <SEP> 287#178t <SEP> .19 <tb> 20.5 <SEP> +0.6 <SEP> +1.2 <SEP> 0/10 <SEP> 1075 <SEP> .73 <SEP> 1053#297t <SEP> .68 <tb> 8.19 <SEP> +0.5 <SEP> +0.8 <SEP> 0/10 <SEP> 1277 <SEP> .87 <SEP> 1375#685 <SEP> .89 <tb> Untreated <tb> cotrols <SEP> +0.6 <SEP> +1.4 <SEP> 0/10 <SEP> 1731# <SEP> 1661#374# <tb> <SEP> +0.6 <SEP> +1.7 <SEP> 0/10 <SEP> 1141#-1470 <SEP> 1474#690#-1545#543 <tb> <SEP> +1.1 <SEP> -0.1 <SEP> 0/10 <SEP> 1418# <SEP> 1474#690# <tb> <SEP> +0.9 <SEP> +2.0 <SEP> 0/10 <SEP> 1617# <SEP> 1699#517# <tb> <RTI ID=17.2> a N.P. = mice without palpable tumors on day 14/total b T/C = ratio of tumor in treated group relative to untreated controls t = Significantly different from untreated control at 0 < .01 by Student's t test qD = daily dosage, days 1 to 5 EXAMPLE 5 Ethyl vinyl ether/Maleic anhydride Copolymer Derivative Polymer was synthesized by reaction in a 3n0 ml, jacketed resin pot under nitrogen blanket at 30 C over a 5 hour period. The resin pot was charged with 12.25 g maleic anhydride and 75 ml THF. Triethylborane was added during the 5 hour reaction period at about 0.008 ml/minute for a total of 2.5 ml. A second monomer solution consisting of 12 ml (9 g) ethyl vinyl ether, 38 ml THF and 0.5 ml t-butylhydroperoxide was added to the resin pot over the 5 hour reaction period at about 0.16 ml/min. via a ln0 cc syringe attached to an infusion pump. At the end of the reaction period, the polymer was precipitated out into hexane, filtered and dried in a vacuum oven at 90 C overnight. Yield = 18.9 g; sp. visc. (0.5X wt/vol in THF at 25 0C)= 0.0199 17.0 g of the above-prepared polymer was ammoniated by first dissolving it in about 150 ml THF and then adding the resulting solution to 200 ml ammonia-saturated THF in a 500 ml, 4-neck flask. Anhydrous ammonia was bubbled in throughout the reaction period at about 7 ml/minute. The addition produced an exotherm and after returning to room temperature the reaction was terminated. The resulting ammoniated polymer was then filtered and dried in a dessicator under vacuum overnight. Substantially all of the above ammoniated polymer was refluxed in toluene for 4 hours with a slight bubbling in of anhydrous ammonia during the reaction period in a 500 ml, 4-neck flask equipped with a water trap. The solid product was recovered in the same manner as the amide-imide polymer derivative of Example 1. Imide = 14Z 15-9 g of the above-prepared amide-imide polymer derivative was mixed with about 150 ml of distilled water and the pH adjusted to 9.5 with concentrated NH4OH. The resulting solution was filtered through a 0.22 F filter and freeze dried prior to submission for pharmaceutical evaluation. Yield = 14.4 g Analysis: C = 49.9, H = 7.45%, N = 12.11% EXAMPLE 6 Butyl vinyl ether/Maleic anhydridel Maleimide Terpolymer Derivative Polymer was synthesized substantially as in Example 3 except that the amount of maleic anhydride used was 11.0 g and the amount of maleimide used was 1.2 g. Yield = 19.1 g; sp. visc. (0.5X in THF at 250C) = 0.0265 17.7 g of the above-prepared polymer was ammoniated and then dried as in Example 3 except that the rate of polymer solution addition was 9 ml/minute. Imide = 6% Substantially all of the ammoniated polymer derivative was mixed with about 250 ml distilled water and the pH adjusted to 9.5 with concentrated NH4OH. The resulting solution was filtered through a 0.20 p filter and freeze dried prior to submission for pharmaceutical evaluation. Yield = l8.9 g Analysis: C = 44.75, H = 7.t0X, N = 10.9 ¯* EXAMPLE 7 2¯chloroethyl vinyl ether/ Maleic anhydride Copolymer Derivative Polymer was synthesized by reaction in a 300 ml, jacketed resin pot under nitrogen blanket at 85 C over a 5 hour period. The resin pot was charged with 12.259 maleic anhydride and 75 ml ethylbenzene. A second monomer solution consisting of 12.7 ml (13.32 g) 2-chloroethyl vinyl ether, 38 ml ethylbenzene and 1 g benzoyl peroxide was added to the resin pot over the 5 hour reaction period at about 0.16 ml/min via a 100 cc syringe attached to an infusion pump. At the end of the reaction period, the polymer was filtered, washed with hexane and dired in a vacuum oven at 90 C overnight. Yield = 20.6 g; sp. visc. (0.5X in THF at 250C) = 0.0235 12 g of the above-prepared polymer was ammoniated by dissolving in 100 ml THF and adding the resulting solution at the rate of 5 ml/minute to ammonia-saturated THF (200 ml) in a 500 ml, 4-neck flak equipped with a mechanical stirrer, thermowell gas dispersion tube and condenser. The addition produced an exotherm ad after returning to room temperature the reaction was terminated. The resulting ammoniated polymer was collected on a glass fritted filter and dried in a dessicator under vacuum overnight. Substantially all of the above ammoniated polymer was refluxed in toluene for 2 hours with a slight bubbling in of anhydrous ammonia during the reaction period. The oolymer product was filtered, washed in hexane and dried in a dessicator under vacuum overnight. The above-prepared amide-imide polymer deriv - ative was dissolved in about 100 ml distilled water and the pH was adjusted to 9.5 with concentrated NH4OH. The resulting solution was filtered through a 0.22 p filter and freeze dried prior to submission for pharmaceutical evaluation. Yield = 10.8 g; Imide = 16% Analysis: C1 = 10.65, C = 39.78X H = 6.46X, N = 10.7% EXAMPLE 8 Butyl vinyl ether/Maleic anhydride/ Maleimide Terpolymer Derivative Polymer was synthesized substantially as in Example 3 except that the resin pot jacket temperature was kept at 800C during the polymerization reaction, and the monomeric solution of butyl vinyl ether, 2,2'-azobis-[2-methyl propionitrile3 and ethylbenzene was introduced to the resin pot at a rate of 0.18 ml/ minute. Yield = 18.4 g; sp. visc. (0.5% in THF at 25 C)= 0.0272 12 g of the above-prepared polymer was ammoniated and then dried substantially as in Example 3. The ammoniated polymer was mixed with about 100 ml distilled water and the pH adjusted to 9.5 with concentrated NH40H. The resulting solution wa s filtered through a 0.2 filter and freeze dried prior to submission for pharmaceutical evaluation. Yield = 12.2 g; Imide = 17% Analysis: C=47.45, H = 7.74%, N = T1.84% EXAMPLE 9 Butyl vinyl ether/Maleic Anhydride Copolymer Derivative Polymer was synthesized by reaction in a 500 ml, jacketed resin pot under nitrogen blanket at 80 0C over a 5 hour period. The resin pot was charged with 24.5 g maleic anhydride and 150 ml ethylbenzene. A second monomer solution consisting of 32.2 ml (25 9) butyl vinyl ether, 75 ml ethylbenzene and 2.0 g 2,2'-azobisC2-methylprpionitrile3 was added to the resin pot over the 5 hour reaction period at about 0.25 ml/minute via a syringe attached to an infusion pump. At the end of the reaction period, the polymer was collected on a glass fritted filter, washed with hexane and dired in a vacuum oven at 90 C overnight. Yield = 25.3 g; sp. visc. < 0.5% in THF at 25 C < =0.0191; sp. visc. < 1.0% in THF at 25 C > = 0.054 12 g of the above-prepared polymer was ammoniated by dissolving in about 100 ml THF and adding the resulting solution at the rate of about 5 ml/minut to anhydrous ammonia-saturated THFC2D0m-1) in a 500 ml, 4-neck flask. The addition produced an exotherm and after returning to room temperature the reaction was termin3ted. The resulting-ammoniated polymer was filtered and dried in a dessicator under vacuum overnight. Imide = OX The above-prepared amidated Copolymer derivative was dissolved in about 150 ml distilled water and the pH was adjusted to 9.5 with concentrated NH4OH. The resulting solution was filtered through a 0.22 filter and freeze dried prior to submission for pharmaceutical evaluation. Yield = 13.0 g EXAMPLE 10 2-Chloroethyl vinyl ether/ Maleic anhydride Copolymer Derivative Polymer Preparation A 300 ml, jacketed resin pot was fitted with a mechanical stirrer, N2 inlet and condenser, glass stopper, and a rubber septum. Water was pumped through the jacket and maintained at a temperature of 75 0C by means of a thermowatch. 12.25 g of maleic anhydride (re-crystallized from chloroform), and 75 ml of ethylbenzene were mixed in the resin pot prior to addition of the following solution: 12.7 ml (13.} y) chloroethyl vinyl ether, I g of azo initiator (same as Example 8) and 38 ml of ethylbenzene. The latter materials were mixed and transferred to a 100 cc glass syringe attached to an infusion pump and connected to the resin pot by means of polyethylene tubing inserted through the rubber septum. This solution was added at 0.16 ml/min. for a total time of 5 hours. The resultant polymer precipitated out into the ethylbenzene. At the end of the addition period, the slurry was cooled to room temperature by circulating cooling water through the jacket. The polymer was then collected on a coarse, fritted glass funnel,washed with hexane and dried in a vacuum oven at 90 C. Yield = 21.4 g; sp. visc. (0.5% in THF at 250C)= 0.0265 Amidation 15 g of the above polymer was dissolved in 100 ml of THF and transferred to a 100 cc glass syringe. The reaction vessel consisted of a 500 ml, 4-neck flask containing 200 ml of THF and fitted with a mechanical stirrer, thermowell, condenser, and a gas dispersion tube. Anhydrous ammonia was bubbled into the THF in the flask for a short while before addition of the polymer and during the reaction. -The polymer solution was added over 20 minutes via the syringe pump set'up. Polethylene tubing from the syringe was inserted down the condenser and into the solvent. The amidated polymer precipitated into the THF and the reaction produced a small exotherm. When the internal temperature returned to room temperature the amidated polymer was collected on a coarse, fritted glass funnel and dried in a dessicator under vacuum. Imide = 0% Freeze Drying All of the above amidated polymer was dissolved in 200 ml of de-ionized H20 and the pH was adjusted to 9.5 with concentrated NHXOH. This solution was filtered through a 0.2yu filter and freeze dried prior to submission for pharmaceutical evaluation. Yield = 15.5 g Analysis: C=40.60X, H = 7.65X, N = 11.70 X, C1 = 11.70% EXAMPLE 11 Samples of the final products prepared for pharmaceutical evaluation in accordance with Examples 5 - 10 above, were tested at various dosages for their antitumor activity against Lewis lung carcinoma substantially in accordance with the procedure set forth in Example 4, above The following Table 4 sets forth the dosages used and the T/C ratio obtained in these tests and compared with controls in male B6D3F1 mice. TABLE 4 EMI26.1 <tb> Dose <SEP> T/C <tb> mg/mg <SEP> Ex. <SEP> 5 <SEP> Ex. <SEP> 6 <SEP> Ex. <SEP> 7 <SEP> Ex. <SEP> 8 <SEP> Ex. <SEP> 9 <SEP> Ex. <SEP> 10 <tb> 2000 <SEP> 0.31 <SEP> Toxic <SEP> Toxic <SEP> Toxic <SEP> Toxic <SEP> Toxic <tb> <SEP> 800 <SEP> 0.52 <SEP> Toxic <SEP> Toxic <SEP> 0.08 <SEP> 0.03 <SEP> Toxic <tb> <SEP> 320 <SEP> 1.03 <SEP> 0.01 <SEP> 0.06 <SEP> 0.04 <SEP> 0.06 <SEP> .09 <SEP> <tb> <SEP> 128 <SEP> 0.75 <SEP> 0.08 <SEP> 0.12 <SEP> 0.25 <SEP> 0.13 <SEP> .09 <tb> <SEP> -51 <SEP> 0.76 <SEP> 0.23 <SEP> 0.35 <SEP> 0.39 <SEP> 0.38 <SEP> .24 <tb> <SEP> 20 <SEP> 0.79 <SEP> 0.33 <SEP> 0.44 <SEP> 0.66 <SEP> 0.48 <SEP> .32 <tb> <SEP> 8 <SEP> 0.79 <SEP> 0.58 <SEP> 0.50 <SEP> 0.79 <SEP> 0.86 <SEP> .53 <tb> In the above exanples, Imide X was deternined by IR spectrometry substantially as described in U.S. Patent 4,255,537.

Claims: WHAT IS CLAIMED IS: 1 . An antitumor active composition of matter selected from the group consisting of low molecular weight co- and terpolymers of lower alkyl- and chloroalkyl-substituted vinyl ethers and maleic anhydride in which from 0 mol percent to about 50 mol percent of the maleic anhydride is replaced with maleimide, said co- and terpolymers having average molecular weights less than about 5000 and derivatized to contain half-amide, half-carboxyl acid groups in which from 0 weight percent to about 25 weight percent of the half-amide, half-carboxyl acid groups are converted to imide groups and the pharmaceutically acceptable cat ironic salt derivatives of said derivatized co- and terpolymers. 2. The composition of matter of Claim 1 in which the derivatized groups are half-amide, half- ammonium salt and imide groups. 3. The composition of matter of Claim 1 in which butyl vinyl ether is copolymerized with maleic anhydride. 4. The composition of matter of Claim 2 in which ethyl vinyl ether is copolymerized with maleic anhydride. 5. The composition of matter of Claim 2 in which butyl vinyl ether is copolymerized with maleic anhydr ide. 6. The composition of matter of Claim 1 in which 2-chloroethyl vinyl ether is copolymerized with maleic anhydride. 7. The composition of matter of Claim 2 in which 2-chloroethyl vinyl ether is copolymerized with maleic anhydride. 8. The composition of matter of Claim 2 in which the butyl vinyl ether is terpolymerized with maleic anhydride and maleimide. 9. A pharmaceutical composition having antitumor activity which comprises, as active ingredient, the composition of matter of Claim 1, in association with a significant amount of a pharmaceutically acceptable carrier. 10. A pharmaceutical composition for parenterat administration and useful for the treatment of Lewis lung carcinoma which comprises, as active ingredient, the composition of matter of Claim 1, in association with a significant amount of a sterile injectable pharmaceutically acceptable carrier. 11. Method for the treatment of Lewis lung carcinoma in a warm blooded animal which comprises administering parenteral ly to said animal an effective amount for inhibitory growth of said carcinoma of the composition of matter of Claim 1.

Inventors: MOTTUS, EDWARD HUGO
Applicants: MONSANTO COMPANY
Application year: 1982
Main classification: A61K31
IPC codes: C08F8, C08L35, A61K31, C08L33, A61P35